FDA Warning Letter to Neil R. Feins, M.D. 2009 05 20 Circare FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures BPC 157 Erectile Dysfunction Study: What the Evidence Actually Shows The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide